STOCK TITAN

PTCT Form 144: 15,705 common shares scheduled for sale on 09/11/2025

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

PTC Therapeutics (PTCT) filed a Rule 144 notice reporting a proposed sale of 15,705 common shares through Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50. The filing lists multiple prior acquisitions of the shares primarily from restricted stock vesting in 2023 and 2024 and from option exercises/grants with specified acquisition dates and quantities. The seller represents they are unaware of undisclosed material adverse information and the form indicates no sales by the person in the prior three months.

Positive

  • Full Rule 144 disclosure provided including broker, share count, aggregate value, and acquisition history
  • Seller attestation that they are not aware of undisclosed material adverse information

Negative

  • Insider selling of 15,705 shares valued at $934,447.50 could be perceived negatively by some investors
  • No 10b5-1 plan date disclosed in the filing, so it is unclear whether the sale follows a pre-established trading plan

Insights

TL;DR: Insider plans to sell 15,705 PTCT shares worth ~$934k on 09/11/2025; acquisitions were mainly vested restricted stock and option-related.

The filing provides clear, required Rule 144 disclosure: broker, exact share count, aggregate value, and acquisition history by date and nature (restricted stock vesting and option grants). This enables investors to track insider liquidity and timing without revealing trading strategy. The absence of reported sales in the prior three months suggests this is not part of a recent frequent-trading pattern by the filer.

TL;DR: The disclosure meets compliance requirements and includes a seller representation regarding material nonpublic information.

The form includes the standard attestation that the seller does not possess undisclosed material adverse information and lists the plan for sale through a named broker. Documentation of acquisition sources (vesting and options) is helpful for transparency around insider compensation realization. No 10b5-1 plan date is provided, so it is not identified whether the sale follows a pre-established trading plan.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by PTCT report?

The form reports a proposed sale of 15,705 common shares via Fidelity Brokerage Services on 09/11/2025 with an aggregate market value of $934,447.50.

Who acquired the shares being sold according to the filing?

The shares were mainly acquired through restricted stock vesting (dates in 2023 and 2024) and from option grants/exercises (notably option grants dated 02/15/2024 and 12/14/2018).

Does the filing indicate prior sales by this person in the last three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer state they possess any material nonpublic information?

By signing the notice, the person represents they do not know of any material adverse information

Through which broker will the PTCT shares be sold?

The shares are to be sold through Fidelity Brokerage Services LLC at the address listed in the filing.
Ptc Therapeutics

NASDAQ:PTCT

PTCT Rankings

PTCT Latest News

PTCT Latest SEC Filings

PTCT Stock Data

5.53B
78.09M
Biotechnology
Pharmaceutical Preparations
Link
United States
WARREN